Hutchmed (China) Limited

Net Asset Value • Mar 23, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0578I

Hutchison China Meditech Limited

23 March 2015

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

2014 Annual Report and

Notice of Annual General Meeting

London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders.  The documents can be accessed from the website of Chi-Med (www.chi-med.com).

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:     +852 2121 8200
Panmure Gordon (UK) Limited	Telephone:     +44 20 7886 2500
Richard Gray Andrew Potts
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:     +44 20 7638 9571 Mobile:           +44 7973 611 888 Mobile:           +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASELFESFISEDD